Cardinal Health CAH Pharmaceutical and Specialty Solutions — D&A

Other segment segments

Similar metrics at other companies

NVSTSpecialty Products & Technologies — D&A

$22.4M+8.7%

PFEBiopharma — D&A

$348M+5.1%

OPKPharmaceutical — D&A

$18.26M+2.7%

CSWSpecialized Reliability Solutions — D&A

$1.63M+19.9%

SCLSpecialty Products — D&A

$1.45M-2.4%

BDXBioPharma Systems — D&A

$27M-15.6%

Questions, answered.

What is Cardinal Health's pharmaceutical and specialty solutions — D&A?

Cardinal Health (CAH) reported pharmaceutical and specialty solutions — D&A of $70M in Q1 2026.

How has Cardinal Health's pharmaceutical and specialty solutions — D&A changed year-over-year?

Cardinal Health's pharmaceutical and specialty solutions — D&A increased by 59.1% year-over-year, from $44M to $70M.

What is the long-term trend for Cardinal Health's pharmaceutical and specialty solutions — D&A?

Over 3 years (2022 to 2025), Cardinal Health's pharmaceutical and specialty solutions — D&A has grown at a 2.9% compound annual growth rate (CAGR), from $170M to $185M.

What does pharmaceutical and specialty solutions — D&A mean?

The non-cash expense allocated to the Pharmaceutical and Specialty Solutions segment to account for the wear and tear of physical assets and the write-off of intangible assets over time. This reflects the ongoing capital investment required to maintain the segment's distribution infrastructure and technology. It is a key component in reconciling net income to cash flow from operations.